Regulation & law · 19/10/1995

Boehringer Ingelheim Pharmaceuticals Inc. Files Request for FDA Approval to Export Atrovent Nasal Spray to Canada

The FDA is announcing that Boehringer Ingelheim Pharmaceuticals Inc. has submitted a proposal to the FDA for the approval of the export of Atrovent (Ipratropium Bromide) Nasal Spray 0.06%, 15 mL to Canada, a move that is part of the company's recently announced expansion plans into the Canadian market.